Upfront stereotactic radiosurgery is associated with improved survival in patients with brain metastases from small-cell lung cancer, compared with whole-brain radiation therapy.

News

Radiation therapy, when given in conjunction with a newly formulated chemotherapy regimen, improves survival rates up to 12 months for patients with inoperable non-small cell lung cancer (NSCLC), according to a recent study.

Read More

Patients with advanced, EGFR-mutant non-small cell lung cancer (NSCLC) lived almost twice as long without disease progression after initial treatment with an EGFR inhibitor compared with standard of care tyrosine kinase inhibitor (TKI) therapy.

Read More

A recent comparison between commonly-used therapies for untreated, advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) demonstrated superior efficacy and lower toxicity for one therapy, published in the New England Journal of Medicine (online August 31, 2017; doi:10.1056/NEJMoa1704795).

Read More

Researchers have identified a new outcome measurement that should be considered a practical clinical end point for early evaluation in emerging therapies for non-small cell lung cancer (NSCLC).

Read More

Research in Review

Patients with cancer who are suffering from depression may be less responsive to cancer drugs and less tolerant of their side-effects, a new study shows.

Read More

Two of the most common chemotherapy regimens may be comparable in terms of efficacy when used in combination with radiotherapy for treatment of non-small cell lung cancer (NSCLC), according to a recent study published in JAMA Oncology.

-----

Related Content

Read More

Patients with early stage metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 have improved quality of life with pembrolizumab treatment versus standard of care platinum-containing chemotherapy, according to new research.

-----

Related Content

Read More

Patients with non-squamous non-small cell lung cancer (NSCLC) have improved progression-free survival (PFS) if they switch from docetaxel to paclitaxel and bevacizumab treatments, according to new research.

-----

Related Content

Read More

Subscribe to Lung Cancer

Ad-Lung Cancer MRC-Desktop Crawler